Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2007 / Article

Original Article | Open Access

Volume 4 |Article ID 621460 | https://doi.org/10.1093/ecam/nel099

Ali Zarei Mahmoudabadi, Muhammad Ali Dabbagh, Zahra Fouladi, "In Vitro Anti-Candida Activity of Zataria multiflora Boiss", Evidence-Based Complementary and Alternative Medicine, vol. 4, Article ID 621460, 3 pages, 2007. https://doi.org/10.1093/ecam/nel099

In Vitro Anti-Candida Activity of Zataria multiflora Boiss

Received15 May 2006
Accepted30 Oct 2006

Abstract

Zataria multiflora Boiss known as Avishan Shirazi (in Iran) is one of the valuable Iranian medicinal plants. The aim of study was to evaluate anti-Candida activity of Z. multiflora against different species of Candida in vitro. Anti-Candida activity of the aqueous, ethanolic and methanolic maceration extract of the aerial parts of Z. multiflora Boiss was studied in vitro. Anti-Candida activity against Candida species was done using serial dilutions of extracts in Sabouraud's dextrose agar. Minimal inhibitory concentration (MIC) of the methanolic and ethanolic extracts was 70.7 and 127 mg l−1, respectively. Aqueous extract showed no remarkable activity against Candida species. We conclude that methanolic extract of the aerial parts of Z. multiflora Boiss has more anti-Candida effect at 70.7 mg l−1 compared to ethanolic extract 127 mg l−1. In addition, the isolates of Candida parapsilosis were more susceptible to methanolic extract than other tested species.

Copyright © 2007 Ali Zarei Mahmoudabadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views130
Downloads700
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.